Clinical Trial Detail

NCT ID NCT01695005
Title A Study of LY3039478 in Participants With Advanced Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

sarcoma

Advanced Solid Tumor

lymphoma

hepatocellular carcinoma

cholangiocarcinoma

chronic lymphocytic leukemia

triple-receptor negative breast cancer

Therapies

LY3039478

Age Groups: adult

No variant requirements are available.